Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)‘s stock had its “outperform” rating reiterated by equities research analysts at Leerink Swann in a research note issued on Monday. They presently have a $7.00 price target on the stock. Leerink Swann’s target price points to a potential upside of 100.00% from the stock’s current price.
Several other equities analysts have also weighed in on the stock. HC Wainwright raised their price objective on shares of Aurinia Pharmaceuticals from $7.00 to $10.00 and gave the company a “buy” rating in a research report on Wednesday, August 17th. FBR & Co reaffirmed an “outperform” rating and set a $9.00 price objective on shares of Aurinia Pharmaceuticals in a research report on Monday, August 15th. Finally, Canaccord Genuity set a $10.00 price objective on shares of Aurinia Pharmaceuticals and gave the company a “buy” rating in a research report on Friday, August 5th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. Aurinia Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $7.75.
Aurinia Pharmaceuticals (NASDAQ:AUPH) opened at 3.50 on Monday. The company’s market capitalization is $123.50 million. Aurinia Pharmaceuticals has a 1-year low of $1.42 and a 1-year high of $4.49. The firm’s 50-day moving average is $2.25 and its 200-day moving average is $2.74.
A hedge fund recently raised its stake in Aurinia Pharmaceuticals stock. Lombard Odier Asset Management USA Corp boosted its position in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) by 2.8% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 102,294 shares of the company’s stock after buying an additional 2,813 shares during the period. Lombard Odier Asset Management USA Corp owned 0.29% of Aurinia Pharmaceuticals worth $283,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 20.04% of the company’s stock.
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.
Receive News & Ratings for Aurinia Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.